Haitong Securities International·2025-10-28 08:08Investment Rating - The report maintains an "Outperform" rating for the company, expecting a relative benchmark index increase of over 10% in the next 12-18 months [20]. Core Insights - The company has raised its full-year performance guidance, anticipating ongoing business revenue growth to shift from 13-17% to 17-18% [4][8]. - As of September 2025, the company's ongoing business orders reached RMB 59.88 billion, reflecting a year-on-year increase of 41.2% [4][8]. - Revenue forecasts for 2025-2027 are projected at RMB 44.02 billion, RMB 48.85 billion, and RMB 55.90 billion, with growth rates of 12.2%, 11.0%, and 14.0% respectively [4][8]. - Net profit attributable to shareholders is expected to be RMB 16.19 billion, RMB 14.68 billion, and RMB 16.88 billion for the same period, with growth rates of 71.3%, -9.3%, and 15.0% respectively [4][8]. - The company’s EPS is projected at RMB 5.42, RMB 4.92, and RMB 5.66 for 2025-2027 [4][8]. Financial Summary - The total revenue for 2023 is reported at RMB 40.34 billion, with a slight increase of 2.5% [3]. - The net profit for 2023 is RMB 9.61 billion, showing a growth of 9.0% [3]. - The company’s net asset return rate is expected to be 21.3% in 2025, with a PE ratio of 19.14 [3][4]. - The small molecule CDMO business reported revenue of RMB 14.24 billion in the first three quarters of 2025, a year-on-year increase of 14.1% [4][8]. - The TIDES business experienced significant growth, with revenue reaching RMB 7.84 billion, up 121.1% year-on-year [4][8]. Business Developments - The company has completed the capacity expansion for polypeptides, with solid-phase synthesis reactors exceeding 100,000L by September 2025 [4][8]. - An agreement was reached to sell 100% of its China clinical service research business for RMB 2.8 billion, while maintaining stable growth in its biological business [4][8]. - The laboratory analysis and testing revenue was RMB 2.96 billion, reflecting a 2.7% year-on-year increase [4][8].